Tighter oversight of manufacturers pricing policies and the competitive environment Its unseemly (polite word choice) that the CEO of Lilly, Dave Ricks, is able to rake in total compensation of $114 million in 2024 while at the same time acknowledging that the price his company charges for Zepbound is too high. Unseemly, because his payday was fueled by Lilly making more than $10 billion in profit from GLP-1s in 2024 alone
There are concerns with some of these online programs that there's not a proper evaluation, there's not a baseline, and there's not proper supervision. The American Telemedicine Association, which advocates for the expansion of digitally enabled care, has not addressed how telehealth providers prescribe GLP-1s, spokesperson Gina Cella said
Keratosis pilaris occurs due to an abnormal buildup of keratin in hair follicles
It could also potentially reduce your resistance to insulin and risk of developing diabetes
MD Anderson Cancer Center notes that evidence suggests GLP-1 agonists like semaglutide may decrease overall cancer risk beyond just the benefits of weight loss
What Is the Actual Molecule in Each One